Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Endocrine therapy is a cornerstone for hormone receptor-positive metastatic breast cancer.
• Tumor biology changes and endocrine resistance limit the long-term effectiveness of these treatments.

Purpose of the Study:

• To review promising new strategies for overcoming endocrine resistance in breast cancer.
• To examine the impact of novel therapies on disease control and quality of life.
• To explore biomarkers for guiding individualized treatment selection.

Main Methods:

• Systematic review of treatments with established benefits.
• Review of emerging agents targeting intracellular signaling pathways.
• Analysis of agents targeting the estrogen receptor (ER), co-signaling pathways, ER chaperones, mutated ERs, and histone acetylation modulators.

Main Results:

• Early encouraging results observed for novel therapeutic agents.
• Focus on agents directly targeting ER, co-signaling pathways, ER chaperones, and histone acetylation.
• Investigating ER antagonists for mutated or activated ERs.

Conclusions:

• Novel therapeutic strategies show promise in overcoming endocrine resistance.
• These approaches aim to improve outcomes for hormone receptor-positive, HER2-negative breast cancer.
• Biomarker identification is crucial for personalized therapy selection.